

BIOLIDICS LIMITED
(Company Registration No.: 200913076M)
(Incorporated in the Republic of Singapore)

PROPOSED ISSUANCE OF UP TO 2,723,500 NEW ORDINARY SHARES IN THE ISSUED AND PAID-UP SHARE CAPITAL OF BIOLIDICS LIMITED (THE "PROPOSED ISSUANCE")

– RECEIPT OF LISTING AND QUOTATION NOTICE

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**") refers to the Company's announcement dated 18 August 2020 in relation to the Proposed Issuance ("**Announcement**"). Unless otherwise defined, capitalized terms used herein shall bear the same meanings ascribed to them in the Announcement.

Further to the Announcement, the Board wishes to announce that the SGX-ST had, on 28 August 2020, granted the listing and quotation notice ("**LQN**") to the Company for the listing of and quotation for up to 2,723,500 New Shares, subject to compliance with the SGX-ST's listing requirements.

The LQN is not an indication of the merits of the Proposed Issuance and the New Shares, the Company, its subsidiaries and their securities.

A separate announcement will be released by the Company upon the allotment and issuance of the New Shares.

BY ORDER OF THE BOARD

Leong Yow Seng
Lead Independent Director
30 August 2020

*This announcement has been prepared by the Company and has been reviewed by United Overseas Bank Limited (the "**Sponsor**") for compliance with Rules 226(2)(b) and 753(2) of the SGX-ST Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Lim Hoon Khiat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*